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Abstract
Genetic damage is a key event in tumorigenesis, and chemically induced genotoxic effects are a human health concern. 
Although genetic toxicity data have historically been interpreted using a qualitative screen-and-bin approach, there is increas-
ing interest in quantitative analysis of genetic toxicity dose–response data. We demonstrate an emerging use of the benchmark 
dose (BMD)-approach for empirically ranking cross-tissue sensitivity. Using a model environmental carcinogen, we quan-
titatively examined responses for four genetic damage endpoints over an extended dose range, and conducted cross-tissue 
sensitivity rankings using  BMD100 values and their 90% confidence intervals (CIs). MutaMouse specimens were orally 
exposed to 11 doses of benzo[a]pyrene. DNA adduct frequency and lacZ mutant frequency (MF) were measured in up to 8 
tissues, and Pig-a MF and micronuclei (MN) were assessed in immature (RETs) and mature red blood cells (RBCs). The 
cross-tissue BMD pattern for lacZ MF is similar to that observed for DNA adducts, and is consistent with an oral route-of-
exposure and differences in tissue-specific metabolism and proliferation. The lacZ MF BMDs were significantly correlated 
with the tissue-matched adduct BMDs, demonstrating a consistent adduct conversion rate across tissues. The BMD CIs, for 
both the Pig-a and the MN endpoints, overlapped for RETs and RBCs, suggesting comparable utility of both cell popula-
tions for protracted exposures. Examination of endpoint-specific response maxima illustrates the difficulty of comparing 
BMD values for a fixed benchmark response across endpoints. Overall, the BMD-approach permitted robust comparisons 
of responses across tissues/endpoints, which is valuable to our mechanistic understanding of how benzo[a]pyrene induces 
genetic damage.
Keywords Benzo[a]pyrene · Mutation · Genotoxicity · Clastogenicity · DNA adducts · BMD
Introduction
Genetic damage is recognized as an enabler of cancer, and 
exposure to genotoxic substances is an important human 
health issue (Hanahan and Weinberg 2011). More spe-
cifically, exposures to genotoxicants can contribute to the 
accumulation of mutations in critical genes, such as tumour 
suppressor or proto-oncogenes (Fearon 1997; Hemminki 
et al. 2000; Wang et al. 2012; Kucab et al. 2015, 2016), and 
this can lead to sustained proliferative signalling, replica-
tive immortality, and evasion of apoptosis and growth sup-
pressors. Although genetic damage can occur and accrue 
spontaneously through endogenous damage and errors in 
replication, it is also induced by exposures to environmen-
tal genotoxicants. Recent high-profile publications have 
re-emphasized the importance of extrinsic factors such as 
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environmental exposures in determining cancer risk (Alex-
androv et al. 2016; Wu et al. 2016).
The pervasive nature of environmental genotoxicants, 
the recognition in the 1970s and early 1980s that humans 
are invariably exposed to environmental mutagens, and 
the established empirical and mechanistic links between 
genetic damage and carcinogenesis, initiated formal chemi-
cal screening programs in Canada, the United States, Japan, 
and Western Europe (MacGregor et al. 2015a). Importantly, 
chemical screening for genetic toxicity is now also motivated 
by recognition that cancer is not the only consequence of 
somatic mutations. Recent research has demonstrated links 
between in utero (geno)toxicant exposures and neurodegen-
erative diseases (Modgil et al. 2014), reproductive defects 
(Fowler et al. 2008; Mocarelli et al. 2011), child develop-
ment (Perera et al. 2015) and somatic mosaicism (Erickson 
2010; Meier et al. 2016).
Traditional screening for chemically induced genetic 
toxicity involves high dose exposures followed by binary, 
qualitative evaluation of the results (i.e., genotoxic or not); 
little quantitative data analysis is conducted. This screen-
and-bin approach is based on the assumption that it is not 
possible to identify a level below which effects are expected 
to be negligible (i.e., indistinguishable from the ever-present 
background); and, moreover, that the relationships between 
exposure and genotoxic effect are linear to zero dose (Health 
Canada 1994; MacGregor et al. 2015a; Pottenger and Gol-
lapudi 2010). This assumption is increasingly being chal-
lenged, and it is now recognized that quantitative analyses 
of dose-related effects can be used to identify a dose below 
which the measured effect level is not significantly elevated 
(Gollapudi et al. 2013; Johnson et al. 2014; MacGregor et al. 
2015b; Speit et al. 2000). However, due to the historical bias 
of examining effects at high doses, with few dose groups, 
determination of an accurate point-of-departure (PoD) (i.e., 
exposure level associated with a pre-defined level of effect) 
is complicated by the necessity to extrapolate below the 
tested doses.
The international genetic toxicology community recently 
examined the use of quantitative dose–response analyses for 
the determination of genetic toxicity PoD values, as well as 
their use to determine human exposure limits for regula-
tory decision-making (Gollapudi et al. 2013; Johnson et al. 
2014). Although several methods can be used to analyze 
dose–response data and generate genotoxicity PoD metrics, 
the aforementioned works of Gollapudi et al. (2013), John-
son et al. (2014), and MacGregor et al. (2015a) expressed a 
distinct preference for the benchmark dose (BMD)-approach. 
The BMD method is a statistical approach for quantita-
tive analysis of dose–response data, whereby a benchmark 
response (BMR) is selected as a pre-defined effect level 
(e.g., 10% greater than control) and the statistically deter-
mined BMD is the best estimation of the dose that will elicit 
this BMR. The approach is flexible with regard to study 
design (e.g., number of dose groups and number of animals) 
and critically, the 90% upper and lower confidence limits on 
the BMD (i.e., the BMDU and BMDL) enable statistically 
rigorous BMD comparisons (Crump 1984; MacGregor et al. 
2015a; Slob 2002).
The BMD approach can be used for a variety of purposes, 
including sensitivity ranking, evaluation of mode-of-action 
(MOA) hypotheses, investigation of empirical relationships 
between genetic toxicity endpoints, and determination of 
exposure limits. For example, we recently used BMD 90% 
confidence intervals (CIs) to conduct potency rankings 
across compounds and exposure regimes, and sensitivity 
rankings across tissues and cell types (Wills et al. 2016a, 
b). The BMD approach for potency or sensitivity ranking is 
superior to comparisons based on the no or lowest observed 
genotoxic effect level (NOGEL or LOGEL), since the PoD 
derived (i.e., the BMD) is not restricted to the selected dose 
groups. Moreover, plotting BMD 90% CIs, and arranging 
them by mid-point, provides a visually intuitive way to com-
pare BMDs and evaluate trends across compounds, sex, cell 
type, tissue, exposure regime and other covariates.
The BMD approach has also proved useful for the dem-
onstration of quantitative relationships between genotoxic-
ity endpoints. Such demonstrations, which could investigate 
relationships between different endpoints or between tissues 
for a single endpoint, can be used to support the involvement 
of specific key events in the MOA to the adverse outcome 
(e.g., cancer). For example, Soeteman-Hernández et al. dem-
onstrated correlations between in vivo genotoxic potency 
(i.e., BMD for induced mutant or micronucleus frequency) 
and carcinogenic potency (Hernández et al. 2011; Soeteman-
Hernandez et al. 2016). However, there is a paucity of data 
to investigate quantitative relationships between several 
well-understood key events, such as DNA adduct formation, 
mutations, and chromosomal damage that are triggered by 
genotoxicants in their carcinogenic MOAs.
Although it is well accepted that a sub-set of DNA 
adducts will contribute to mutation formation (Hemminki 
et al. 2000; Hemminki 1993), there is an acute need for 
research examining quantitative relationships between 
adduct frequency and mutation frequency, especially at low 
doses (Hemminki et al. 2000; Sander et al. 2005). The lack 
of such analyses quantitatively linking in vivo genetic tox-
icity (e.g., frequency of DNA adducts) with in vivo muta-
genicity, across numerous somatic tissues, is likely due to 
the difficulty of making all the required measurements. 
Somatic mutations in vivo are rare and they infrequently 
elicit phenotypic changes; thus chemically induced changes 
in mutant frequency (MF) are notoriously difficult to detect; 
moreover, measurement of DNA damage and MF in the 
same animals constitutes a significant challenge. Although 
endogenous mutation detection systems do exist, they are 
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either laborious, and hence, infrequently used (e.g., Hprt 
mutations), or restricted to haematopoietic tissues (e.g., Pig-
a). Transgenic rodents (TGRs), which employ a bacterial 
target gene in a shuttle vector that can readily be recovered 
from genomic DNA, provide a convenient way to determine 
in vivo MF in any tissue (Lambert et al. 2009).
In this study, we used the prototypical genotoxic carcino-
gen benzo[a]pyrene (BaP), four well-characterized genetic 
toxicity endpoints, and the BMD approach, to scrutinise 
responses at low doses, rank potencies across tissues, and 
compare responses across endpoints. To permit simulta-
neous determination of several endpoints within the same 
animal, we employed the MutaMouse, a CD2F1 transgenic 
mouse containing a lacZ target in a lambda shuttle vector 
(Gossen et al. 1989). We used an extended range of BaP 
doses (i.e., 11 in total) to examine effects at doses below 
the region where significant increases in genotoxicity are 
observed. Although admittedly atypical, the study design 
employed herein affords improved BMD precision and a 
concomitant opportunity to robustly compare responses 
across tissues and endpoints; moreover, to examine empiri-
cal relationships between responses of functionally related 
endpoints (e.g., induced DNA damage and mutations).
Materials and methods
Animal exposures and tissue collection
We selected eleven doses of BaP (CAS # 50-32-8, 
purity ≥ 96%; Sigma-Aldrich Canada, Oakville, ON, Can-
ada), with the top doses based on previous work by our 
group (Lemieux et al. 2011). The selected doses, 0, 0.10, 
0.20, 0.39, 0.78, 1.56, 3.13, 6.25, 12.50, 25.00, and 50.00 mg 
BaP/kg body weight (BW)/day, were delivered in highly 
refined olive oil (Sigma-Aldrich). Adult male MutaMouse 
specimens (12–13 weeks old) were maintained as described 
previously (Long et al. 2016). There were 7 animals in each 
dose group, with 14 animals in the vehicle control group (84 
animals total). Mice received BaP or olive oil by oral gavage 
at 0.005 ml/g body weight daily for 28 days. Two days after 
the final dose, blood was collected from the facial vein for 
MN analysis. A 3-day sampling time was employed for the 
transgene endpoint (OECD 2013), and was also employed 
for the Pig-a endpoint. Mice were anesthetised with isoflu-
rane gas and blood was collected via cardiac puncture for 
scoring Pig-a MF. Additionally at this time, blood was col-
lected from 4 positive control mice that were administered 
80 mg ENU/kg BW i.p., and four vehicle control mice that 
were administered phosphate buffer as single i.p. injection 
3 weeks prior to blood collection. Mice were euthanized 
by cervical dislocation. Mice were bred, maintained, and 
treated in accordance with the Canadian Council for Animal 
Care Guidelines and Health Canada’s Animal Care Commit-
tee. Bone marrow, liver, lung, small intestine, and glandular 
stomach were preserved as described previously (Long et al. 
2016). Kidney, spleen, and bladder were flash frozen in liq-
uid nitrogen. All tissues were stored at – 80 °C.
Preliminary data for bone marrow, liver, small intestine, 
glandular stomach, and lung for the lacZ MF endpoint only 
were previously published in Wills et al.  (2016b); here the 
dataset is expanded with a further two tissues (i.e., kidney 
and spleen) for lacZ, and three additional endpoints.
Peripheral blood micronucleus assay
MicroFlow®-BASIC kits (Litron Laboratories, Rochester, 
NY, USA) were used to prepare blood cells for enumera-
tion of micronucleated reticulocytes (MN-RET) and normo-
chromatic erythrocytes (MN-NCE) at Litron Laboratories, 
as previously described (Long et al. 2016). Frozen, coded 
samples were shipped on ice to Litron Laboratories for scor-
ing by flow cytometry using a three-colour labelling method 
as previously described (Dertinger et al. 2004).
Pig‑a mutant scoring in peripheral blood
Following blood collection via cardiac puncture, 100 µl of 
blood was immediately transferred to a 0.5 mL K2-EDTA-
coated microtainer (VWR). Whole blood samples were 
placed in an ExactPak shipping container and shipped on 
ice overnight to Litron Laboratories. Flow cytometric scor-
ing of Pig-a MF was conducted at Litron via  MutaFlow® 
Kit reagents according to their published immunomagnetic 
enrichment method (Dertinger et al. 2011), with modifica-
tions for scoring in mouse (Labash et al. 2016). Based on 
these analyses, the number of Pig-a mutant cells per million 
were calculated for RETs as well as total red blood cells 
(RBCs).
DNA extraction
Bone marrow, glandular stomach, liver, small intestine, and 
lung were prepared for an overnight digestion in lysis buffer 
as described previously (Long et al. 2016). Spleen, kidney, 
and bladder were prepared for overnight lysis and genomic 
DNA extraction as follows: approximately ¼ of the spleen, 
½ of a kidney, or the entire bladder was defrosted on ice and 
minced into small pieces. The minced tissue was transferred 
to a tube containing 5 ml lysis buffer [1 mM  Na2EDTA, 
100 mM NaCl, 20 mM Tris–HCl, pH 7.4, 1% SDS (w/v)] 
and incubated overnight at 37  °C with gentle shaking. 
Genomic DNA was isolated from lysed tissue using a phe-
nol/chloroform extraction procedure described previously 
(Douglas et al. 1994; Vijg and Douglas 1996). Isolated DNA 
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was dissolved in 50–100 µl TE buffer (10 mM Tris pH 7.6, 
1 mM EDTA) and stored at 4 °C until use.
32P‑postlabelling for DNA adduct analysis
Bulky DNA adduct formation was analysed in DNA sam-
ples from liver, lung, bone marrow, glandular stomach, 
small intestine, spleen, kidney, and bladder via the nuclease 
P1 enrichment version of the thin-layer chromatography 
32P-postlabelling assay (Phillips and Arlt 2014). The pro-
cedure was performed as described previously (Krais et al. 
2016; Wohak et al. 2016), and results are expressed as DNA 
adducts/108 nucleotides.
Positive selection for lacZ mutants
The PGal (phenyl-β-d-galactoside) positive selection assay 
was carried out for the analysis of lacZ MF in DNA sam-
ples from spleen and kidney as previously described (Gossen 
et al. 1992; Lambert et al. 2005; Vijg and Douglas 1996). 
MF was calculated as the ratio of mutant plaque forming 
units (pfu) to total pfu. The lacZ MF could not be scored 
in bladder as there was insufficient DNA remaining follow-
ing DNA adduct analysis. The lacZ MF data for bone mar-
row, glandular stomach, small intestine, liver, and lung was 
recently published in Wills et al. (2016b), and these data 
were included in the analyses presented below.
Statistical analysis
Statistical analysis for the determination of a treatment effect 
for all endpoints was carried out in SAS v.9.1 (SAS Institute, 
Cary, NC, USA) by applying a Type 3 Chi-square analysis 
and employing a Poisson regression, in the same manner as 
described previously (Long et al. 2016). Post-hoc custom 
contrasts based on the asymptotic Chi-square distribution 
of the likelihood ratio statistic were conducted to compare 
each dose group with the control.
Benchmark dose modelling
BMD analyses were conducted using the PROAST software 
(version 50.9—http://www.proast.nl). Dose–response data 
were analysed using a family of nested exponential models 
(Slob 2002) recommended by the European Food Safety 
Authority for the assessment of continuous data (EFSA 
2009). PROAST uses the likelihood ratio test to select the 
optimal model, with increasingly complex models using 
additional parameters only accepted if the difference in log-
likelihood exceeds the critical value of p < 0.05. The BMR 
selected for the current analyses (i.e., 100% or a two-fold 
increase in the response relative to control), was chosen as 
it is commonly used for the assessment of genotoxicity data, 
and because it tended to lie within the range of experimental 
observation in the datasets herein as was thus ‘optimal’ for 
deriving CIs for sensitivity comparison (Wills et al. 2016a). 
The BMDL and BMDU values represent the lower and upper 
bounds of the two-sided 90% CI of the BMD, respectively, 
with the difference between the BMDU and BMDL defin-
ing the uncertainty in the BMD estimate and, therefore, its 
precision. As employed in previous work, CI plots arranged 
by the geometric midpoint of the BMDL-BMDU interval 
were utilised to permit robust sensitivity comparisons that 
account for estimation uncertainty (Bemis et al. 2016; Wills 
et al. 2016a).
To evaluate the relationship between lacZ BMDs 
and adduct BMDs, the visual approach used by Bemis 
et al. (2016) and Soeteman-Hernández et al. (2016) was 
employed. This approach simply draws a line with unity 
slope through the double-log plot; the unity slope translates 
into a proportional relationship between the endpoint BMDs 
on the original axes scales.
Results
No overt signs of toxicity (i.e., body weight change, liver 
somatic index) were observed in any dose group, includ-
ing controls. A significant level of induction of each genetic 
damage endpoint was observed in all tissues examined, 
although the responses occurred at different dose levels 
and the magnitude of the response varied across endpoints. 
Using PROAST, we employed the exponential model family 
to derive the  BMD100 and accompanying 90% CIs (i.e., the 
BMDL and BMDU values). The  BMD100, BMDL, BMDU, 
along with the BMDU-BMDL ratio for each tissue and end-
point are summarised in Supp. Table I, and BMD model fits 
for each analysis are presented in Supp. Figure 1a–d. The 
CIs (i.e., range between the BMDL to BMDU) bounding 
the  BMD100 values were used for comparative evaluations 
of tissue sensitivities.
DNA adduct frequency
Using an external BaP-diol-epoxide-DNA standard (Phillips 
and Castegnaro 1999), the major DNA adduct detected was 
identified as dG-N2-BPDE (10-(deoxyguanosin-N2-yl)-7,8,9-
trihydroxy-7,8,9,10-tetrahydro-BaP), with BaP-DNA 
adducts being detected in all seven tissues examined (Supp. 
Figure 2). The first dose in which we observed a significant 
increase in adduct frequency over control (i.e., the LOGEL) 
was 0.20 mg/kg BW/day for spleen, 0.39 mg/kg BW/day 
for bladder, 0.78 mg/kg BW/day for bone marrow, liver, 
small intestine, lung, and kidney, and 1.56 mg/kg BW/day 
for glandular stomach (Fig. 1a; Supp. Figure 3). The highest 
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fold change increase in DNA adduct levels over control was 
observed in spleen (506-fold), followed by lung (433-fold), 
liver (219-fold), kidney (187-fold), bladder (139-fold), glan-
dular stomach (46.3-fold), small intestine (27.4-fold), and 
bone marrow (19.6-fold).
To visualize the difference in tissue sensitivities, the 
BMD CIs for each tissue were plotted using a  log10-scale 
(Fig.  1b). In this way, tissues with non-overlapping 
BMD CIs can be sequentially ranked by sensitivity, with 
decreasing sensitivity shown from left to right (i.e., lowest 
to highest BMD). This method for the illustration of sensi-
tivity trends is superior to the common approach of simply 
listing the BMD/BMDL/BMDU values in a table (Supp. 
Table I), as upon inspection of Fig. 1b it is immediately 
apparent that the sensitivity order is: small intestine/bone 
marrow/spleen/glandular stomach/lung/bladder/kidney/
liver. Due to the relatively large BMD CI for some tis-
sues (e.g., 5 of 8 tissues had BMDU-BMDL ratios over 2, 
Supp. Table I), there is some overlap in the BMD range of 
all adjacent tissues. However, it is still possible to obtain 
mechanistic information from these results; and, moreover, 
conclude that the sensitivity of small intestine and bone 
marrow are significantly higher than lung, bladder, kidney, 
and liver. It is also interesting to note that the sensitiv-
ity order obtained via BMD-modelling is not the same 
as the order of tissues according to the level of induced 
response (i.e., maximum fold-change over control), nor 
the order determined using lowest significant dose (i.e., 
the LOGEL).
Fig. 1  The frequency of BaP-induced DNA adducts was evaluated 
in 8 tissues. a BaP dose–response data (±  standard error) for DNA 
adducts plotted using a  log10 y-axis for better visualisation of the 
responses across all doses. Statistical results for the overall dose–
response relationship are presented for each tissue. The level of sig-
nificance for the custom contrast results for each dose vs. control are 
indicated as follows: a = p < 0.0001; b = p < 0.001; c = p < 0.01; 
d = p < 0.05. BM bone marrow, Lv liver; GS glandular stomach; SI 
small intestine; Lg lung; Sp spleen; Kd kidney; Bd bladder. Asterisk 
indicates where responses were below 1, and thus are obscured on a 
 log10 scale. Supp. Figure 3 shows dose–response data plotted on a lin-
ear scale with a restricted y-axis to visualise the low-dose responses. 
b  BMD100 values and two-sided 90% CIs (i.e., the range between 
the BMDL and BMDU) determined using the exponential model for 
DNA adducts. BMDs can be considered different where CIs do not 
overlap
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lacZ mutant frequency
A significant induction in lacZ MF was observed in all tis-
sues examined, with LOGELs of 1.56 mg/kg BW/day for 
small intestine, 3.13 mg/kg BW/day for bone marrow and 
spleen, 6.25 mg/kg BW/day for lung and glandular stomach, 
12.5 mg/kg BW/day for kidney, and 25 mg/kg BW/day for 
liver (Fig. 2a). The highest fold change increase over control 
was observed in small intestine (208-fold), followed by bone 
marrow (120-fold), spleen (81.0-fold), glandular stomach 
(28.6-fold), liver (14.6-fold), lung (14.1-fold), and kidney 
(5.0-fold). As Fig. 2b illustrates, there were considerable dif-
ferences in BMDs across tissues, with the sensitivity order 
as follows: small intestine > spleen or bone marrow > glan-
dular stomach or lung > liver or kidney. Despite minor dif-
ferences, it is apparent that this sensitivity trend is similar to 
that observed for DNA adduct frequency. However, for the 
lacZ endpoint the BMDs were more precise (i.e., all BMDU-
BMDL ratios below 2; Supp. Table I), which resulted in 
fewer overlapping CIs. As a result, it is possible to distin-
guish lacZ sensitivity values between additional tissues, and 
in fact, to visualise three discrete groupings of tissues (i.e., 
small intestine > bone marrow/spleen > kidney/liver/lung/
stomach). In this case, the sensitivity order is fairly similar 
to the order according to induced response and LOGEL.
Pig‑a mutant frequency in peripheral blood
Pig-a mutant phenotype frequency was examined in both 
RETs and RBCs. A significant positive increase was 
observed in both cell populations, with the first signifi-
cant response (i.e., the LOGEL) appearing at 12.5 mg/
kg BW/day in both RETs and RBCs (Fig. 3a). The fold-
increase over control observed for RBCs (69.7-fold) was 
Fig. 2  The frequency of BaP-induced lacZ mutants was evaluated in 
seven tissues. a BaP dose–response data (± standard error) for lacZ 
mutations, plotted using a  log10 y-axis for better visualisation of the 
responses across all doses. Statistical results for the overall dose–
response relationship are presented for each tissue. The level of sig-
nificance for the custom contrast results for each dose vs. control are 
indicated as follows: a = p < 0.0001; b = p < 0.001; c = p < 0.01; 
d = p < 0.05. BM bone marrow; Lv liver; GS glandular stomach; SI 
small intestine; Lg lung; Sp spleen; Kd kidney. b  BMD100 values and 
two-sided 90% CIs (i.e., the range between the BMDL and BMDU) 
determined using the exponential model for lacZ mutations. BMDs 
can be considered different where CIs do not overlap
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only 1/5 as high as for RETs (385.5-fold). The BMD CIs 
for RETs and RBCs overlapped (Fig. 3b), therefore, a 
sensitivity order could not be established. This is inter-
esting given the large difference in response magnitudes; 
however, the trend across these two cell populations is 
analogous to the observed cross-tissue trend in sensitiv-
ity to adduct formation (i.e., overlapping BMD ranks). In 
this case, issues related to the detection of the Pig-a MF 
resulted in reduced sample size that likely contributed 
to increases in the BMD CIs. In fact, the Pig-a BMDU-
BMDL ratio is over 2 for both cell populations, whereas 
the lacZ BMDU-BMDL ratio is below 2 for all tissues 
examined.
Percent micronuclei in red blood cells
The frequencies of micronucleated RETs and NCEs were 
examined to assess BaP-induced chromosomal damage. A 
significant increase in the percent micronucleated cells was 
observed in both RETs and NCEs at 3.13 mg/kg BW/day 
(Fig. 4a). A slightly higher fold-change increase over control 
was observed in RETs (4.5-fold), in comparison with NCEs 
(3.7-fold). The ranges between the BMDL and BMDU over-
lapped (Fig. 4b), therefore, a sensitivity order could not be 
determined. The ratio of BMDU to BMDL was well below 
2, indicating that BaP is similarly clastogenic in both cell 
populations.
Fig. 3  The frequency of BaP-
induced Pig-a mutant pheno-
type was evaluated in peripheral 
blood. a BaP dose-response 
data (± standard error) for Pig-a 
mutations. Statistical results 
for the overall dose–response 
relationship are presented for 
both cell populations. The level 
of significance for the custom 
contrast results for each dose vs. 
control are indicated as follows: 
a = p < 0.0001; b = p < 0.001; 
c = p < 0.01; d = p < 0.05. 
RET reticulocyte; RBC red 
blood cell. b  BMD100 values 
and two-sided 90% CIs (i.e., the 
range between the BMDL and 
BMDU) for Pig-a mutations for 
both cell populations Where CIs 
overlap tissue responses cannot 
be considered different
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Comparisons of endpoint‑specific BMDs 
for hematopoietic tissues
Finally, we compared sensitivity across each endpoint for 
hematopoietic tissues. To do this, the 90% CIs for each 
hematopoietic tissue  BMD100 were plotted together for vis-
ual comparison across the endpoints examined (Fig. 5a). 
The figure shows a progression of  BMD100 values across 
endpoints from DNA adducts (i.e., lowest BMD), to lacZ 
and Pig-a mutants at doses approximately 25- to 90-fold 
higher, and finally, to chromosome damage at doses 2- to 
4.5-fold higher than the mutant endpoints and 150- to 350-
fold higher than for DNA adducts (Supp. Table I). Thus, 
the observed pattern of BMDs in hematopoietic tissues 
seems consistent with the sequence of key events leading 
from genetic damage to cancer.
Although Fig. 5a supports the contention that sequential 
genotoxic events precede tumor formation (Fukushima et al. 
2016; MacGregor et al. 2015b) the manner in which the data 
are presented raises fundamental questions about the validity 
of such cross-endpoint comparisons. Figure 5b uses identical 
fixed y-axes to compare the modelled dose–responses for 
each endpoint in hematopoietic tissue (RBCs only for Pig-a, 
NCEs only for MN). By plotting the responses on the same 
y-axis scale, it becomes readily apparent that the inducible 
range in response varies considerably across endpoints (e.g. 
a small dynamic range in inducible response is particularly 
noticeable for the micronucleus endpoint). Additionally, 
Fig. 4  The frequency of BaP-
induced MN was evaluated 
in peripheral blood. a BaP 
dose-response data (± standard 
error) for micronuclei. Statisti-
cal results for the overall dose–
response relationship are pre-
sented for both cell populations. 
The level of significance for the 
custom contrast results for each 
dose vs. control are indicated 
as follows: a = p < 0.0001; 
b = p < 0.001; c = p < 0.01; 
d = p < 0.05. RET reticulo-
cyte; NCE normochromatic 
erythrocyte. b  BMD100 values 
and two-sided 90% CIs (i.e., the 
range between the BMDL and 
BMDU) for % micronuclei for 
both cell populations. Where 
CIs overlap tissue responses 
cannot be considered different
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model parameter ‘c’ displayed in the inset, which is the 
model-determined estimate of the maximum response, 
shows nearly a 10-fold reduction between the DNA adduct 
and MF endpoints, and an approximately 25-fold reduction 
between the MF and micronucleus endpoints (Fig. 5b).
Empirical relationship between genotoxic 
sensitivity and mutagenic sensitivity
When visually comparing the dose–response data for DNA 
adduct frequency (Fig. 1a) with that for lacZ MF (Fig. 2a), 
there is no apparent empirical relationship between the tis-
sue-specific induced damage levels. To examine the empiri-
cal relationship between these two endpoints, tissue-matched 
 BMD100 values, and their associated 90% CIs, were plotted 
against each other. To quantitatively scrutinise the correla-
tion on the double-log axes, a diagonal line with unity slope 
(i.e., slope = 1) was overlaid on the plotted data (Fig. 6). If 
Fig. 5  The observed pattern of hematopoietic tissue BMDs showing 
important differences in the maximum response across endpoints. 
a  BMD100 values and two-sided 90% confidence intervals (i.e., the 
range between the BMDL and BMDU) for each endpoint in hemat-
opoietic tissue. b Illustration of fitted functions on a fixed y-axis 
showing variations in maximum response, indicated by model param-
eter ‘c’ (inset), across endpoints. The horizontal dashed lines indicate 
the BMR on the Y-axis, and the vertical dashed lines indicate the 
BMD on the X-axis
Fig. 6  The empirical relationship between genotoxic sensitivity and 
mutagenic sensitivity of BaP (i.e.,  BMD100 values and two-sided 90% 
CIs for the DNA adduct endpoint vs. tissue-matched  BMD100 values 
and two-sided 90% CIs for the lacZ mutation endpoint). A line with 
unity slope is indicated, which, on a double-log plot, demonstrates 
proportionality between the responses. BM bone marrow; Lv liver; GS 
glandular stomach; SI small intestine; Lg lung; Sp spleen; Kd kidney
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the BMDs for the various tissues scatter randomly around 
the unity line, and the unity line appears to be a good repre-
sentation of the data, this shows that the mutant and adduct 
BMDs are proportionally related on the original scales. The 
analysis, which is shown in Fig. 6, indeed demonstrated a 
proportional relationship between genotoxic sensitivity (i.e., 
induction of DNA adducts), and mutagenic sensitivity (i.e., 
induction of lacZ mutants) across seven tissues. Critically, 
this proportionality suggests that, despite large differences 
in cross-tissue BMDs for a given endpoint, tissue-specific 
conversion of adducts to mutations is likely consistent.
As cellular replication is a necessary factor for muta-
tion fixation, we also wanted to investigate the influence of 
cellular proliferation on the conversion of DNA adducts to 
mutants. As part of our standard experimental protocol, we 
evaluated proliferation rate, as Ki-67 index, in liver, lung, 
and small intestine (Supp. Methods). The Ki-67 index plot-
ted against the ratio of DNA adduct BMD to lacZ MF BMD 
for these three tissues (Supp. Figure 4), is positively cor-
related. Although this correlation is based on only three tis-
sues, it supports the notion that cellular proliferation rate 
affects the tissue-specific conversion of BaP-induced DNA 
adducts to mutations.
Discussion
The quantitative assessment of genetic toxicity data is a rap-
idly advancing field, and the emerging application of the 
BMD-approach to derive PoDs has well-described advan-
tages for regulatory decision-making and the protection of 
human health. Here, we present an advanced approach for 
BMD-modeling that allows for robust cross-tissue sensitivity 
ranking, thereby contributing important quantitative support 
for tissue-specific genotoxic effects. More specifically, this 
study used the BMD-approach to model BaP-induced in vivo 
genetic toxicity dose–response relationships across several 
tissues and an expanded dose range, and derived  BMD100 
values and their associated 90% CIs for each tissue/end-
point combination. We subsequently employed the BMD 
CIs to conduct sensitivity ranking across eight tissues for 
DNA adducts, seven tissues for lacZ mutants, and 2 periph-
eral blood cell populations for both Pig-a MF and MN. As 
discussed below, examinations of tissue rankings for each 
endpoint, and empirical relationships between the endpoints, 
permitted general statements about the fundamental nature 
of the endpoints examined and the mechanistic relationships 
between the damage types.
It is well recognized that BaP primarily induces tumors 
via a genotoxic mode-of-action; specifically, via the conver-
sion of bulky DNA adducts to point mutations that confer 
the hallmark properties of a cancerous cell (Hanahan and 
Weinberg 2011; IARC 2010b). Although not the primary 
mechanism, BaP is also known to induce micronuclei, as 
double strand breaks may be formed as a result of replica-
tion fork stalling and collapse (Bi et al. 2005). Following 
oral exposure, BaP has been shown to induce carcinomas 
in the oral cavity, forestomach, liver, and small intestine of 
male and female Wistar rats, and kidney, mammary, and 
skin carcinomas in male Wistar rats (Kroese et al. 2002). 
Oral administration to various mouse strains resulted in 
tumours in lymphoid and haematopoietic tissues, as well as 
in lung, forestomach, liver, esophagus, and tongue (IARC 
2012). BaP also caused forestomach carcinomas, malignant 
lymphomas in lymphatic organs including the spleen, and 
bronchiolar-alveolar hyperplasia in the lung of male Muta-
Mouse specimens orally exposed for only 5 days (Hakura 
et al. 1998). It is, therefore, not unexpected that we were 
able to detect significant increases in BaP-induced geno-
toxicity for all four endpoints in all tissues/cell populations 
examined, namely DNA adducts and lacZ mutants in bone 
marrow, glandular stomach, small intestine, liver, lung, kid-
ney, spleen, and bladder (adducts only); as well as Pig-a MF 
and chromosome damage in peripheral blood cells. With 
respect to DNA damage, we were able to detect a significant 
increase in DNA adducts at 0.20 mg BaP/kg BW/day, the 
lowest oral dose used to date to investigate the in vivo geno-
toxicity of BaP. This robust genotoxic response demonstrates 
the utility of the MutaMouse TGR assay for simultaneously 
investigating several, complementary genetic toxicity end-
points across numerous tissues.
Ranking sensitivity across the measured tissues lends 
support for mechanistic understanding of the toxicologi-
cal properties of the compound evaluated. In this study, we 
observed that the Pig-a and MN BMD CIs overlapped for 
RETs and RBCs/NCEs, and, therefore, a sensitivity order 
could not be established between the two cell populations. 
This may simply be due to the accuracy of the measure-
ment of these endpoints, with larger CIs being more likely to 
result in overlap. However, for the MN endpoint in particu-
lar, the BMDU-BMDL ratio is below 2 and is quite similar 
for both cell populations, therefore, alternatively, this may 
indicate that RETs and NCEs are equally sensitive to MN 
induction by BaP. Therefore, that there may be comparable 
utility in examining either cell population for study designs 
that involve protracted exposures, such as the one conducted 
here. Our novel approach to data analysis makes a direct 
comparison of our results with other publications using 
these endpoints difficult. However, in a recent paper we 
employed the BMD method to examine dose–response data 
from a Pig-a study examining the genotoxicity of N-ethyl-
N-nitrosourea, and in that case, the BMD CIs for RBCs and 
RETs overlapped (Wills et al. 2016b), as they did in the 
current study. Conversely, the CIs for RBCs sampled at dif-
ferent time points were distinct (Wills et al. 2016b), which 
highlights that sampling time appears to be more important 
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for RBCs than for RETs. Notably, for both the Pig-a and 
MN endpoints, far fewer RETs are interrogated than NCEs/
RBCs, and this contributes to larger CIs. Additional use 
of the BMD approach will permit similar cross-cell com-
parisons for different species, experimental designs, and 
compounds.
The DNA adduct and lacZ MF sensitivity rankings 
resulted in very similar cross-tissue patterns; however, there 
was considerably more overlap in CI range across tissues 
for DNA adducts than for lacZ MF. This is likely a result of 
the fact that the lacZ MF data permit determination of more 
precise BMDs (as demonstrated by the smaller BMDU-
BMDL ratio), allowing for greater sensitivity discrimina-
tion between tissues.
For both DNA adducts and lacZ MF, the cross-tissue 
pattern in responses is likely controlled by four factors: 
(1) tissue contact, (2) tissue-specific metabolism and the 
extent of systemic circulation of the parent compound and 
activated metabolites, (3) tissue-specific proliferation rate, 
and (4) tissue-specific differences in DNA repair capacity. 
As discussed in our recent manuscript (Wills et al. 2016b), 
the fact that small intestine was the most sensitive tissue 
for induction of lacZ mutants, and similarly, as seen here, 
for DNA adducts, is consistent with an oral route of expo-
sure and the known metabolic capacity of this tissue. BaP 
itself is not DNA-reactive. Its major genotoxic pathway 
(i.e., via cytochrome P450 CYP1A1/1A2/1B1 metabolism) 
is induced following aryl-hydrocarbon (AhR)-agonism 
(Shimada et al. 2002; Shimada and Fujii-Kuriyama 2004; 
Xue and Warshawsky 2005), and leads to the conversion 
of BaP into the genotoxic metabolite BaP-7,8-dihydrodiol-
9,10-epoxide (BPDE). BPDE exerts its mutagenic effect by 
covalently binding primarily to purines, causing a bulky 
DNA adduct, which if not repaired prior to DNA replica-
tion, can result in a mutation (IARC 2014). Two alternate 
activation pathways for BaP are also recognized, namely the 
PAH-radical-cation pathway, which results in depurinating 
adducts, and the ortho-quinone pathway, which can generate 
covalent DNA adducts or oxidative DNA damage (Penning 
2014). However, this study, which employed 32P-postlabe-
ling, only examined the frequency of BPDE-type adducts. 
Although ingested BaP would reach the stomach first, the 
small intestine is known to have much higher levels of 
Cyp1a1 expression (Choudhary et al. 2003; Renaud et al. 
2011) and, therefore, absorption by the small intestine would 
likely result in greater conversion to BPDE, a concomitant 
increase in damage in this tissue, and a higher sensitivity 
(i.e., lower BMD) in comparison with stomach (Figs. 1b, 
2b). Furthermore, BaP is known to undergo enterohepatic 
circulation (Miller and Ramos 2001; Ramesh et al. 2004), 
which causes cycling of BaP and its activated metabolites 
between the liver and the small intestine via the bile. This 
would permit re-exposure of the small intestine and liver to 
BPDE, leading to an increase in bulky adducts and, in turn, 
mutations. Taken together, the high level of tissue contact 
and effective metabolism in this tissue would certainly con-
tribute to the high sensitivity in small intestine, as seen here.
As with the site-of-contact tissues, the spleen and bone 
marrow were quite sensitive to the induction of both DNA 
adducts and lacZ mutants. These are both distal tissues that 
require systemic circulation of BaP and/or activated metabo-
lites for exposure to occur. BaP is well known to induce 
significant immunotoxicity in rodent models (Blanton et al. 
1986; De Jong et al. 1999; Dean et al. 1983; Ginsberg et al. 
1989), which appears to be at least partially mediated by 
cytotoxicity related to DNA adduct formation (Ginsberg 
et al. 1989). The lymphatic system, including the spleen, is 
also a target organ for tumors (lymphomas) in orally exposed 
MutaMouse (Hakura et al. 1998), and XPA-deficient mice 
(IARC. 2010a; Van Oostrom et al. 1999). CYP1B1 in the 
spleen and bone marrow appears to mediate the conversion 
of BaP to BPDE (Heidel et al. 1998; Uno et al. 2006) with 
several studies also suggesting the possibility that splenic 
exposure to BPDE is also occurring as a result of extra-
splenic metabolism (Ginsberg et al. 1989; Ginsberg and 
Atherholt 1990). Specifically, BPDE in the blood can be 
sequestered by the serum (Ginsberg and Atherholt 1989) 
and transported to the spleen, where it is released and taken 
up by splenocytes (White et al. 1994). The results presented 
herein likely indicate that substantial levels of BaP are avail-
able for systemic circulation, and support the high sensitivity 
observed for both bone marrow and spleen.
The cross-tissue sensitivity ranking for the lacZ endpoint 
also highlights the likely role of tissue-specific proliferation, 
since the sensitivities for tissues with higher proliferative 
rates (i.e., small intestine, spleen, bone marrow, glandular 
stomach) were higher than tissues with slower rates of pro-
liferation (i.e., lung, liver, kidney). For example, the sensi-
tivity of the hepatic lacZ response is the lowest (i.e., highest 
BMD), and this is consistent with a relatively low prolif-
eration rate in comparison with the other tissues examined. 
In order for bulky adducts to result in sequence changes, 
DNA replication is a necessary process, therefore, tissues 
that are not actively undergoing cellular proliferation would 
accrue fewer mutants in a given period of time, whereas a 
tissue with a higher mitotic index would be likely to accrue 
far more mutants. It is known that spleen (Muskhelishvili 
et al. 2003), bone marrow (White et al. 2017), glandular 
stomach (Merritt et al. 1997; Ozkan et al. 2001; Radulescu 
et al. 2010; Snipes 1967), and small intestine (Muskhel-
ishvili et al. 2003; White et al. 2017) have mitotic indices 
that are at least an order of magnitude higher than those of 
slower proliferating tissues such as liver (White et al. 2017), 
lung (Shami and Evans 1992), and kidney (Eldridge and 
Goldsworthy 1996). These higher replication rates would be 
expected to contribute to higher mutagenic efficiency (i.e., 
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conversion of stable DNA adducts to mutations), higher 
mutant responses for a given dose, and a concomitantly 
lower BMD (i.e., lower sensitivity), which is consistent 
with our results. In fact, when we plotted the Ki-67 index 
for liver, lung, and small intestine against the ratio of the 
 BMD100 of DNA adducts to  BMD100 of lacZ mutations 
(Supp. Figure 4), we obtained a significant positive corre-
lation. Taken together, the data presented here and in the 
literature highlight the importance of tissue-specific cellu-
lar proliferation in the conversion efficiency of stable DNA 
adducts to mutations.
The tissue-specific difference in DNA-repair capac-
ity is also likely to contribute to the observed sensitivity 
pattern across tissues. Recent in vitro studies of potent 
alkylating agents have demonstrated that inactivation of 
 O6-methylguanine DNA methyltransferase (MGMT) can 
shift the PoD for mutation and chromosome damage to the 
left (i.e., more potent) (Thomas et al. 2013; Zair et al. 2011), 
whereas murine overexpression of the same repair pathway 
moves the PoD for tumor formation induced by alkylating 
agents significantly to the right (i.e., less potent) (Becker 
et al. 2014). Although differences in repair capacity across 
various tissues have not been fully explored, it is likely that 
tissue-specific differences in the presence and activity of 
certain DNA repair genes will affect the rate of conversion 
of bulky adducts to mutations. This is consistent with the 
aforementioned work of Thomas et al. (2015), which noted 
that the four key proteins involved in nucleotide excision 
repair (i.e., the pathway associated with BPDE removal) can 
be induced by genotoxic stress.
The direct comparison of BMDs across endpoints is an 
approach used to permit ranking of mechanistically sequen-
tial endpoints (Fukushima et al. 2016; Moffat et al. 2015; 
Thomas et  al. 2007). The approach, which is borrowed 
from chemical risk assessors’ practice of employing the 
most sensitive endpoint (i.e., lowest NOAEL) for regulatory 
decision-making, involves ordering endpoints that represent 
a series of plausible key events, and then comparing PoD 
metrics across these endpoints. When the  BMD100 values 
calculated here are compared across all hematopoietic tissue 
endpoints (Fig. 5a), the observed BMD pattern is consistent 
with the sequence of key events leading from genetic dam-
age to cancer. At first glance this is intuitive, as we expect 
DNA adducts to occur at a dose that is only limited by test 
article absorption, metabolism, and distribution, and tissue 
exposure to activated metabolites. Adducts may be repaired, 
however; and only when this response becomes over-
whelmed, presumably at a higher dose, would we expect to 
see mutations and/or chromosome damage. Thus, the BMD 
for the next endpoint in the series (i.e., mutations) would 
be expected to be equal to or higher than that for adducts 
(Meek et al. 2014), as we found here with the BMD for lacZ 
mutants in bone marrow, which preceded that for Pig-a MF. 
The lower BMD for lacZ mutants is likely a result of the 
fact that lacZ is a multi-copy silent transgene (Shwed et al. 
2010), whereas Pig-a is an active, single copy endogenous 
gene (Phonethepswath et al. 2008). As such, lacZ transgene 
DNA is not subject to transcription-coupled repair (Lam-
bert et al. 2005), resulting in a higher MF for a given dose 
(i.e., lower BMD) in comparison with an endogenous gene 
like Pig-a. Finally, MN are the result of a relatively narrow 
range of damage types (i.e., double strand breaks or whole 
chromosome loss) (Fenech et al. 2011), in comparison with 
point mutations that can accrue via a range of processes 
(e.g., base-pair substitutions, frame-shifts, deletions) (Lam-
bert et al. 2005). Therefore, it is logical that a higher BMD 
would be observed for the MN endpoint than for the mutant 
endpoints, as we see here.
Although the aforementioned approach, which orders 
PoD across a series of sequential endpoints, is mechanis-
tically appealing, we contend that it is inappropriate to 
directly compare BMDs across endpoints with different 
dynamic ranges of inducible responses (Fig. 5b). As speci-
fied in Slob (2017) endpoints with very large inducible 
ranges (i.e., many fold changes between control response 
and maximum inducible response) can be expected to 
yield very low BMD values as it requires very little effort 
to move the response above background to the BMR. This 
is especially apparent when comparing an endpoint with a 
relatively high theoretical maximum and very low detection 
limit (e.g., DNA adducts) to an endpoint such as % MN. For 
the MN endpoint, the maximum response generally observed 
is ten- to 20-fold above background (Fig. 5b); in contrast, 
the observed maximum responses for the DNA adduct and 
lacZ mutant endpoints are 100- to 1000-fold above back-
ground. This difference alone, regardless of the endpoints’ 
sequential involvement in the determination of the adverse 
outcome, will contribute to a BMD series, for a set BMR, 
whereby adduct frequency is lowest, followed by mutation 
and chromosomal damage. The problem is further illustrated 
by consideration of the cancer endpoint, which is highly con-
strained with respect to maximum response, as the data are 
quantal (i.e., animals are tumor bearing or not). Therefore, at 
a BMR of 100, 100% of the animals are tumor bearing, and 
thus it is not possible to have an effect size > 100%. How-
ever, for continuous endpoints, a BMR of 100 simply reflects 
a two-fold doubling of control, which is, in comparison, a 
small, and relatively easily achieved effect size (Sander et al. 
2005). A 10% increase in the incidence of cancer may be of 
concern, but, in contrast, a 10% increase in adduct frequency 
may not constitute a significant disease-related change given 
the relative ease with which the latter endpoint can be moved 
away from the background. The approach presented by Slob 
(2017) to correct for cross-endpoint differences in theoretical 
maximum, will be applied to this and other genetic toxicity 
datasets in a forthcoming manuscript.
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Recent works by Soeteman-Hernández et al. employed 
the BMD approach to examine empirical relationships 
between several genetic toxicity and carcinogenicity end-
points (Hernández et al. 2011; Soeteman-Hernandez et al. 
2015, 2016). However, there is a paucity of data examining 
quantitative relationships between DNA damage sensitiv-
ity (i.e., adduct sensitivity) and mutagenic sensitivity. In 
our study, when examining the relationship between DNA 
adducts and lacZ mutants, we were only able to see a cross-
tissue relationship when the comparison was based on the 
BMD metric. This is the first demonstration of an empirical 
relationship between DNA adduct induction and mutation 
induction across several tissues. For BaP, the results suggest 
a consistent, proportional conversion of adducts to muta-
tions across tissues. DNA adduct frequency is a biomarker 
of exposure, whereas mutations and chromosomal damage 
are biomarkers of effect and, therefore, DNA adduct data are 
currently used in more of a qualitative manner to establish 
exposure and genotoxic potential of a compound (Sander 
et al. 2005). Additional research will be required to demon-
strate whether proportionality between DNA adducts and 
mutations exist for other chemicals, but if this is confirmed, 
it may enable us to reliably use DNA adduct data in a more 
quantitative manner. This would be advantageous since 
DNA adduct frequency is much more readily assessed across 
tissues, and does not require the use of transgenic rodents.
Finally, it is important to note that this novel analysis 
approach need not be restricted to newly generated data such 
as those presented here. Analysis of published data, such as 
that previously presented by our group (Wills et al. 2016a, 
b), can permit the determination of potency or sensitivity 
rankings across compounds, tissues, cell types, and/or expo-
sure regimens. The results of such analyses can reduce the 
necessity of additional studies, thus contributing to an over-
all reduction in animal use without sacrificing the precision 
of metrics used for human health risk assessment.
Conclusions
We documented BaP-induced genetic damage across all 
endpoints and tissues examined, even at very low doses 
(e.g., 0.2 mg/kg BW/day for spleen adducts). By ranking 
BMD CIs across tissues for a given endpoint, we observed 
that sensitivity varied significantly across tissues in 
regards to induced lacZ MF, and the differences were more 
pronounced in comparison with the DNA adduct endpoint. 
We were unable to observe cell population-specific sen-
sitivity differences for Pig-a MF and MN frequency end-
points. We demonstrated that the cross-tissue BMD trend 
was similar for both DNA adducts and lacZ mutants, and 
that this trend is consistent with tissue-specific differences 
in metabolism, proliferation, and repair. Moreover, we 
showed quantitative evidence that cross-tissue  BMD100s 
for DNA adduct induction are proportional to  BMD100s for 
lacZ mutant induction, illustrating that the tissue-specific 
conversion of adducts to mutations is likely consistent, 
and that this empirical dependency is consistent across 
the seven tissues examined. Finally, our cross-endpoint 
comparisons of  BMD100 values raised questions regarding 
the validity of comparisons based on a fixed BMR value. 
Cross-endpoint comparisons of BMD metrics using a fixed 
BMR have become unfortunately common, but this work 
and the earlier work of Slob (2017) indicate that, for com-
parisons to be meaningful, BMR values must be scaled 
according to endpoint-specific theoretical maxima. Over-
all, the BMD-approach employed herein permitted robust 
comparisons of responses across tissues and endpoints, 
and the information obtained adds valuable information 
to our mechanistic understanding of how BaP induces an 
array of genetic damage across several tissues. BMD rank-
ings within an endpoint, and empirical comparisons across 
endpoints, contribute to an improved understanding of tis-
sue-specific, chemically induced genetic damage, and this 
knowledge can provide a foundation for the selection of 
tissues, endpoints and BMRs for use in human health risk 
assessments. To enhance current understanding regarding 
the tissue-specific fixation of chemically induced genetic 
damage, future work should continue to examine the cross-
tissue relationships between chemically induced mutations 
and/or chromosomal damage and induced DNA damage.
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